<DOC>
	<DOCNO>NCT01643850</DOCNO>
	<brief_summary>This study , design proof concept study MCS110 pigment villonodular synovitis , assess clinical response MCS110 treatment Pigmented Villonodular Synovitis ( PVNS ) Giant cell tumor tendon sheath ( GCTTS ) patient multiple intravenous dos MCS110 use magnetic resonance image assess tumor volume , evaluate pharmacokinetics/pharmacodynamics , safety tolerability population .</brief_summary>
	<brief_title>MCS110 Patients With Pigmented Villonodular Synovitis ( PVNS ) Giant Cell Tumor Tendon Sheath ( GCTTS )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Synovitis , Pigmented Villonodular</mesh_term>
	<criteria>Inclusion criterion : Patients PVNS GCTTS , least , one measurable site disease MRI . Vital sign within range : systolic blood pressure 80150 mmHg , diastolic blood pressure 50100 mmHg , pulse rate 40100 bpm , oral body temperature 35.037.5Â°C . Patients normal level serum ionized calcium phosphate . Women childbearing potential must use highly effective contraception study 84 day study drug infusion . Exclusion criterion : Patients PVNS GCTTS whose tumor evaluable MRI , judgment central MRI reading site . Patients major surgery le 3 month prior start study drug still side effect therapy . Presence systemic illness preclude definitive surgery increase risk patient due potential immunosuppression . Use previously intraarticular treatment within 4 week prior dose . Patients dermal change indicative lymphedema phlebolymphedema . disease . Patients elevate troponin T and/or CK level ( &gt; 1.5 x ULN laboratory ) history myositis , rhabdomyolysis myopathic disease . Evidence liver disease liver injury indicate abnormal liver function test SGOT ( AST ) , SGPT ( ALT ) , gamma GT , alkaline phosphatase , serum bilirubin . Patients receive immunosuppressive treatment well corticosteroid discontinue least 4 week dose . Patients engage resistance exercise training program . Patients concomitant disease know get influence bone metabolism Patients history drug alcohol abuse within 12 month prior study dose . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pigmented Villonodular Synovitis</keyword>
	<keyword>PVNS</keyword>
	<keyword>Giant cell tumor tendon sheath</keyword>
	<keyword>GCCTS</keyword>
	<keyword>Tenosynovial giant cell tumor ( localize diffuse type )</keyword>
	<keyword>MCS110</keyword>
</DOC>